<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938625</url>
  </required_header>
  <id_info>
    <org_study_id>CR102639</org_study_id>
    <secondary_id>TMC435HPC3016</secondary_id>
    <secondary_id>2013-002726-23</secondary_id>
    <nct_id>NCT01938625</nct_id>
  </id_info>
  <brief_title>A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation</brief_title>
  <official_title>Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen R&amp;D Ireland</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen R&amp;D Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate effect of steady-state (when the amount of drug
      administered (in a given time period is equal to the amount of drug eliminated in that same
      period) of simeprevir and daclatasvir on the steady-state pharmacokinetics (what a medication
      does to the body) of cyclosporine (applicable to Part 1 only) and tacrolimus when
      administered as a combinational regimen in post-orthotopic liver transplantation (OLT)
      participants with recurrent hepatitis C virus (HCV) genotype 1b infection and effectiveness
      of a 24-week treatment regimen containing simeprevir, daclatasvir, and ribavirin (RBV) with
      respect to the proportion of HCV genotype 1b infected post-OLT participants achieving
      sustained virologic response 12 weeks after end of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (all participants of this study know the identity of the intervention)
      and multicenter (study conducted at multiple sites) study. This study will be conducted in 2
      parts. Both the parts of the study will consist of screening phase (4 weeks), treatment
      period (24 weeks), and a post-treatment follow-up (24 weeks). A total of 30 participants will
      be enrolled in Part 1 and Part 2 of the study. A minimum of 9 participants were planned to
      receive cyclosporine as stable immunosuppressant therapy and a minimum of 9 participants were
      planned to receive tacrolimus as stable immunosuppressant therapy during Part 1. All
      participants will be receiving tacrolimus as stable immunosuppressant therapy during Part 2.
      In Part 1 of the study, participants with Metavir score of F1-F2, will receive a combination
      of study drugs - simeprevir, daclatasvir, and ribavirin for 24 weeks. In Part 2 of the study,
      participants with Metavir score F1-F4 will receive a dosing regimen of study drugs based on
      the data from Part 1 of the study. Safety evaluations will include assessments of adverse
      events, clinical laboratory tests, urinalysis, electrocardiogram, vital signs, and physical
      examination. The total study duration for each participant will be approximately 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a sustained virologic response (SVR)12 Weeks after the end of treatment</measure>
    <time_frame>Week 36</time_frame>
    <description>Participants are considered to have achieved SVR12 if HCV RNA levels are less than (&lt;) 25 international unit per milliliter (IU/mL) detectable or undetectable at 12 weeks after end of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of cyclosporine and tacrolimus</measure>
    <time_frame>Pre-dose (within 15 minutes before the intake of cyclosporine or tacrolimus) and at 1, 2, 3, 4, 5, 6, 7, 9, 12, and 24 hours postdose at Baseline and Week 2 (with study drugs simeprevir , daclatasvir and ribavirine)</time_frame>
    <description>The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of cyclosporine and tacrolimus</measure>
    <time_frame>Pre-dose (within 15 minutes before the intake of cyclosporine or tacrolimus) and at 1, 2, 3, 4, 5, 6, 7, 9, 12, and 24 hours postdose at Baseline and Week 2 (with study drugs simeprevir , daclatasvir and ribavirine)</time_frame>
    <description>The Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) is a measure of the plasma concentration cyclosporine and tacrolimus from time zero to end of dosing interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of simeprevir and daclatasvir</measure>
    <time_frame>Pre-dose (within 15 minutes before the intake of simeprevir and daclatasvir) and at 1, 2, 3, 4, 5, 6, 7, 9, 12, and 24 hours postdose at Week 2 and 2 weeks after any dose adjustments</time_frame>
    <description>The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of simeprevir and daclatasvir</measure>
    <time_frame>Pre-dose (within 15 minutes before the intake of simeprevir and daclatasvir) and at 1, 2, 3, 4, 5, 6, 7, 9, 12, and 24 hours postdose at Week 2 and 2 weeks after any dose adjustments</time_frame>
    <description>The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose (trough) concentration (C0h) of simeprevir and daclatasvir</measure>
    <time_frame>Pre-dose (within 15 minutes before the intake of simeprevir and daclatasvir) at Week 2 and 2 weeks after any dose adjustments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of simeprevir and daclatasvir</measure>
    <time_frame>Pre-dose (within 15 minutes before the intake of simeprevir and daclatasvir) at Week 2 and 2 weeks after any dose adjustments</time_frame>
    <description>The Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) is a measure of the plasma concentration of simeprevir and daclatasvir from time zero to end of dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with dose adjustment of cyclosporine and tacrolimus during treatment with regimen simeprevir, daclatasvir and RBV</measure>
    <time_frame>Week 1 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a sustained virological response SVR4 after the end of treatment</measure>
    <time_frame>Week 28</time_frame>
    <description>Participants are considered to have achieved SVR4 if HCV RNA levels are less than (&lt;) 25 international unit per milliliter (IU/mL) detectable or undetectable at 4 weeks after end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a sustained virologic response SVR24 after the end of treatment</measure>
    <time_frame>Week 48</time_frame>
    <description>Participants are considered to have achieved SVR24 if HCV RNA levels are less than (&lt;) 25 international unit per milliliter (IU/mL) detectable or undetectable at 24 weeks after end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Undetectable HCV RNA (less than 25 IU/mL undetectable) and HCV RNA less than 25 IU/mL detectable</measure>
    <time_frame>Weeks 2, 4, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with HCV RNA level less than 100 IU/mL</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with on-treatment failure after treatment with regimen simeprevir, daclatasvir and RBV</measure>
    <time_frame>Screening, Baseline and Week 1 to 24</time_frame>
    <description>On-treatment failure is defined as HCV RNA level is greater than or equal to 25 IU/mL at end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with viral relapse after treatment with regimen simeprevir, daclatasvir and RBV</measure>
    <time_frame>Screening, Baseline, Week 1 to 24; 24 Weeks after end of treatment</time_frame>
    <description>Viral relapse is defined as undetectable HCV RNA less than 25 IU/mL at end of treatment and greater than or equal to 25 IU/mL during the follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with HCV NS3/4A and NS5A sequences</measure>
    <time_frame>Screening, Baseline and Week 1 upto 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver transplant between 6 months and 10 years prior to the screening visit

          -  Hepatitis C virus (HCV) genotype 1 subtype b infection confirmed at screening

          -  Screening HCV ribonucleic acid level greater than 10,000 IU/mL

          -  HCV treatment-na√Øve participants must not have received post orthotopic liver
             transplant treatment with any approved or investigational drug for the treatment of
             HCV

          -  Receiving stable immunosuppressant therapy (ie, no change in dose in the last month)
             with cyclosporine (only allowed in Part 1) or tacrolimus for more than 3 months prior
             to the screening visit

        Exclusion Criteria:

          -  Evidence of acute or chronic hepatic decompensation after the liver transplantation
             (including ascites, bleeding varices or hepatic encephalopathy)

          -  Any liver disease of non-HCV etiology, including current evidence of graft rejection
             except the presence of liver steatosis

          -  Any other clinically significant disease that in the opinion of the investigator would
             be exacerbated by the known effects of ribavirin

          -  Coinfection with HCV of another genotype than genotype 1b, HIV type 1 or 2 (positive
             HIV-1 or HIV-2 antibodies test at screening), and hepatitis B virus (hepatitis B
             surface antigen positive)

          -  Multi-organ transplant that included heart, lung, pancreas, or kidney
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen R&amp;D Ireland Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen R&amp;D Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <disposition_first_submitted>April 5, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 5, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 4, 2016</disposition_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Recurrent Chronic Hepatitis C</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Simeprevir</keyword>
  <keyword>Daclatasvir</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Orthotopic Liver Transplantation</keyword>
  <keyword>TMC435</keyword>
  <keyword>BMS-790052</keyword>
  <keyword>RBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 29, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

